Kintor Pharmaceutical Limited
Kintor Pharmaceutical Limited, a clinical-stage novel drug developer, focuses on developing small molecules and biologic drugs for dermatology and oncology in the People's Republic of China. Its product candidates include KX-826, a potential topical drug for the treatment of androgenic alopecia (AGA) and acne vulgaris, which is in phase III clinical trial; and GT20029, a topical AR-PROTAC compoun… Read more
Kintor Pharmaceutical Limited (KNTPF) - Total Assets
Latest total assets as of June 2025: $391.89 Million USD
Based on the latest financial reports, Kintor Pharmaceutical Limited (KNTPF) holds total assets worth $391.89 Million USD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Kintor Pharmaceutical Limited - Total Assets Trend (2014–2024)
This chart illustrates how Kintor Pharmaceutical Limited’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Kintor Pharmaceutical Limited - Asset Composition Analysis
Current Asset Composition (December 2024)
Kintor Pharmaceutical Limited's total assets of $391.89 Million consist of 33.3% current assets and 66.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 28.6% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $2.21 Million | 0.4% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $157.28 Million | 30.5% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2014–2024)
This chart illustrates how Kintor Pharmaceutical Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Kintor Pharmaceutical Limited's current assets represent 33.3% of total assets in 2024, a decrease from 93.0% in 2014.
- Cash Position: Cash and equivalents constituted 28.6% of total assets in 2024, up from 15.0% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 30.0% of total assets, an increase from 0.0% in 2014.
- Asset Diversification: The largest asset category is intangible assets at 30.5% of total assets.
Kintor Pharmaceutical Limited Competitors by Total Assets
Key competitors of Kintor Pharmaceutical Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Kintor Pharmaceutical Limited - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Kintor Pharmaceutical Limited generates 0.01x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Kintor Pharmaceutical Limited is currently not profitable relative to its asset base.
Kintor Pharmaceutical Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.44 | 1.56 | 8.39 |
| Quick Ratio | 0.42 | 1.56 | 8.39 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-79.59 Million | $ 133.09 Million | $ 1.25 Billion |
Kintor Pharmaceutical Limited - Advanced Valuation Insights
This section examines the relationship between Kintor Pharmaceutical Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.88 |
| Latest Market Cap to Assets Ratio | 0.15 |
| Asset Growth Rate (YoY) | -40.7% |
| Total Assets | $515.13 Million |
| Market Capitalization | $77.25 Million USD |
Valuation Analysis
Below Book Valuation: The market values Kintor Pharmaceutical Limited's assets below their book value (0.15 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Kintor Pharmaceutical Limited's assets decreased by 40.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Kintor Pharmaceutical Limited (2014–2024)
The table below shows the annual total assets of Kintor Pharmaceutical Limited from 2014 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $515.13 Million | -40.74% |
| 2023-12-31 | $869.23 Million | -57.70% |
| 2022-12-31 | $2.06 Billion | -0.62% |
| 2021-12-31 | $2.07 Billion | +11.69% |
| 2020-12-31 | $1.85 Billion | +334478.12% |
| 2019-12-31 | $553.38K | +30.64% |
| 2018-12-31 | $423.60K | -99.14% |
| 2017-12-31 | $49.14 Million | +189.89% |
| 2016-12-31 | $16.95 Million | -57.75% |
| 2015-12-31 | $40.11 Million | +198.35% |
| 2014-12-31 | $13.45 Million | -- |